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Abstract
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration to lung cancer
patients is common owing to the few options available. Impact of clinical factors on prognosis of EGFR-mutant
non-small cell lung cancer (NSCLC) patients receiving EGFR-TKI readministration after first-line EGFR-TKI failure and
a period of TKI holiday remains unclear. Through this retrospective study, we aimed to understand the impact of
clinical factors in such patients.
Methods: Of 1386 cases diagnosed between December 2010 and December 2013, 80 EGFR-mutant NSCLC patients
who were readministered TKIs after failure of first-line TKIs and intercalated with at least one cycle of cytotoxic agent
were included. We evaluated clinical factors that may influence prognosis of TKI readministration as well as systemic
inflammatory status in terms of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR).
Baseline NLR and LMR were estimated at the beginning of TKI readministration and trends of NLR and LMR were
change amount from patients receiving first-Line TKIs to TKIs readministration.
Results: Median survival time since TKI readministration was 7.0 months. In the univariable analysis, progression free
survival (PFS) of first-line TKIs, baseline NLR and LMR, and trend of LMR were prognostic factors in patients receiving
TKIs readministration. In the multivariate analysis, only PFS of first-line TKIs (p < 0.001), baseline NLR (p = 0.037), and
trend of LMR (p = 0.004) were prognostic factors.
Conclusion: Longer PFS of first-line TKIs, low baseline NLR, and high trend of LMR were good prognostic factors in
EGFR-mutant NSCLC patients receiving TKI readministration.
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Background
Lung cancer is the leading cause of cancer-related deaths
in Taiwan and worldwide [1, 2]. Although epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) are administered as standard first-line regimen
for advanced EGFR-mutant non-small cell lung cancer
(NSCLC) [3–5], the salvage treatment for cases with
acquired resistance to EGFR-TKIs remains unclear. Owing
to several barriers including difficulty of tumor re-biopsy,
absence of EGFR T790m mutation or programmed death-
ligand 1 expression, and high expenses, some patients do
not have an opportunity to receive novel agents such as
3rd generation TKI [6] or immunotherapies [7, 8].
In patients with acquired resistance to EGFR-TKIs,
readministration of first or second generation EGFR-TKIs
has been proved to effectively increase patients’ survival
time [9–11]. In non-selective patients, EGFR-TKI readmi-
nistration has only modest efficacy with a progression free
survival (PFS) of 2–4 months [10, 12]. However, in opti-
mal selected patients, patients could have a PFS of more
than 6 months [10]. Although several good prognostic fac-
tors for patients receiving TKI readministration have been
reported, such as EGFR-TKI free holidays, better Eastern
Cooperative Oncology Group performance status, and
benefit from prior EGFR-TKI therapy [10–12], little is
known about the correlation between systemic inflamma-
tory markers and TKI readministration efficacies. In previ-
ous studies, several systemic inflammatory markers were
found to be prognostic factors in lung cancer patients.
NSCLC patients with higher blood neutrophil-to-
lymphocyte ratio (NLR) had poor prognosis when treated
with a combination of bevacizumab and cytotoxic agents
[13]; those with higher lymphocyte-to-monocyte ratio
(LMR) had better prognosis in EGFR-mutant NSCLC pa-
tients receiving first-line EGFR-TKIs [14].
Based on these aforementioned reasons we performed a
retrospective study to understand the impact of clinical
factors including NLR and LMR on EGFR-mutant NSCLC
patients receiving TKI readministration. To decrease the
impact of confounding factors, we only included EGFR-
mutant NSCLC patients receiving TKI readministration as
third or later line therapies after failure of first-line EGFR-
TKIs and at least one cycle of intercalated chemotherapy.
Methods
Patients and clinical characteristics
We conducted a retrospective study between December
2010 and December 2013 at Kaohsiung Chang Gung
Memorial Hospital in Taiwan. Patients were followed-up
until November 2015. Adult patients aged ≥18 years
with histologically or cytologically confirmed stage IIIB
or IV NSCLC who had been treated with first line
EGFR-TKIs and received TKIs readministration were in-
cluded. Patients who had received a second TKI without
intercalating with at least one cycle of cytotoxic chemo-
therapies were excluded.
Baseline assessments including clinical parameters,
hematological variables, biochemistry, chest radiography,
and chest computed tomography were performed within
4 weeks of initiation of TKI readministration.
Clinical parameters included length of TKI holiday
and PFS of study patients receiving first line EGFR-TKIs.
Data regarding hematological parameters were collected
within 4 weeks of the initiation of first-line TKI therapy
and also TKI readministration including neutrophil,
lymphocyte, and monocyte counts. NLR was obtained by
dividing the neutrophil count by the lymphocyte count,
and LMR was obtained by dividing the lymphocyte
count by the monocyte count. Baseline NLR and LMR
were estimated at the beginning of TKI readministration
and trends of NLR and LMR were obtained by dividing
the data estimated at the beginning of TKI readministration
with the data estimated at the beginning of first-line TKIs.
This study was approved by the Institutional Review
Board of Kaohsiung Chang Gung Memorial Hospital.
The need for informed consent was waived.
EGFR mutation testing
Tumor specimens were obtained by bronchoscopy CT-
guided biopsy, pleural effusion cytology, or surgical pro-
cedures. The EGFR mutational analyses was performed
using SCORPIONS and ARMS polymerase chain reaction
using fragments amplified from genomic DNA extracted
from paraffin-embedded tissues (QIAGEN EGFR RGQ
PCR KIT). Exon 19 deletion and L858R mutations were
defined as common mutations. Other mutations or com-
pound mutations were defined as uncommon mutations.
Evaluation of response to EGFR-TKI readministration
Patients underwent routine chest radiography every
2–4 weeks and chest computed tomography every 2–
3 months to evaluate tumor responses. PFS was de-
fined as the time between the first day of EGFR-TKI
administration and disease progression, death before
documented progression, or the last visit during the
follow-up period. Disease progression was determined
by the clinician according to the Response Evaluation
Criteria in Solid Tumors criteria 1.1 [15]. The end-
point was overall survival (OS), which was defined as
the first day of EGFR-TKI readministration until
death, or the last visit during the follow-up period.
Statistical analyses
Statistical analyses were performed using MedCalc
(version 14.10.2). Receiver operating characteristic (ROC)
curves with binary variable of OS longer or shorter than
7.0 months since readministration and Youden’s index
were used to determine the best cut-off value for baseline
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values of and trends of NLR LMR as a prognostic factors.
OS analyses were performed using the Kaplan-Meier
method and the log-rank test. Cox proportional hazards
regression test were used to evaluate independent factors.
P value < 0.05 was considered significant in statistical tests.
Results
Patient characteristics
Between December 2010 and December 2013 1386 lung
cancer cases were diagnosed. Of these, 269 patients had a
positive EGFR mutation status and were treated with first-
line EGFR-TKIs, and 80 patients were readministered TKIs
with at least one cycle intercalated cytotoxic agent (Fig. 1).
Lines and regimens of Intercalated chemotherapies were
shown in Additional file 1: Table S1. The median follow-up
time since readministration was 7.0 months the longest
follow-up duration was 20.4 months. At the end of follow-
up 78.8 % (63/80) patients showed disease progression
under TKI readministration and 36.3 % (29/80) patients
were alive. Baseline values and trends of hematological pa-
rameters were available for 78 and 77 patients, respectively.
To evaluate baseline values and trends of NLR and LMR,
using ROC curve analysis, we determined that the best
cut-off values were 5.2, 1.1, 2.5, and 0.5, respectively.
Impact of clinical factors on overall survival of TKI
readministration
Clinical factors found to be significant in the univariable
analysis for poor OS since TKI readministration included
shorter PFS of first-line TKI (p = 0.020) (Fig. 2) high
baseline NLR (p < 0.001) (Fig. 3a), low baseline LMR
(p = 0.006B), and low trend of LMR (p = 0.037) (Fig. 4)
(Table 1).
Length of TKI holiday changes in the TKI regimen,
and first or second generation TKIs when TKI readminis-
tration, and trend of NLR did not significantly influence
OS. In the multivariable analysis, independent prognostic
factors for shorter OS were shorter first-line TKI PFS
(p < 0.001), high baseline NLR (p = 0.037), and low
trend of LMR (p = 0.004) (Table 1).
Discussion
Our retrospective observational study found that base-
line NLR and trend of LMR as well as PFS of first-line
EGFR-TKI treatment were prognostic factors in patients
receiving TKI readministration. NLR was previously
found to have a prognostic effect in different types of
cancer like ovarian cancer, breast cancer, pancreatic
Fig. 1 Inclusion, screening, and assignment of patients into groups
Fig. 2 Overall survival since the readministration of tyrosine
kinase inhibitors of patients with short (<6 months), intermediate
(6–12 months), and long (>12 months) progression free survival of
first-line tyrosine kinase inhibitors
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cancer, and colorectal cancer, as well as in advanced
NSCLC patients treated with first-line platinum-based
chemotherapy [16–21]. LMR was found to be a prognos-
tic factor in small cell lung cancer [22], in early-stage
NSCLC patients post operation [23], in advanced lung
cancer treated with cytotoxic chemotherapies [24], and
in EGFR-mutant lung cancer patients treated with first-
line EGFR-TKIs [14]. Several possible mechanisms may
explain the prognostic effect of these pro-inflammatory
markers. First, neutrophils release several pro-angiogenic
factors and promote angiogenesis, which is essential for
tumor progression. Second, lymphocytes play a pivotal role
in tumor cell eradication [25], and tumor-associated mac-
rophages promote tumor progression through remodeling
of the tumor extracellular matrix [26, 27]. Based on the
above pathophysiology, patients with high NLR and low
LMR tend to have tumor progression and fewer T cells
available for cancer cell eradication.
Previous studies have reported conflicting results re-
garding the influence of PFS of previous EGFR-TKI on
the efficacy of TKI readministration. In one study that
included all patients without TKI holidays longer PFS of
previous TKI treatment paradoxically shortened the PFS
of TKI readministration [11]. Another study in which
52 % of patients with a TKI holiday before TKI rechal-
lenge revealed that PFS of previous TKI treatment was
not related with the efficacy of TKI readministration
[12]. By excluding patients without having TKIs holi-
days, our study revealed that patients with a longer PFS
of previous TKI treatment have a longer OS of TKI
readministration. In the first study, the authors specu-
lated that in patients who received previous therapy for
less than 12 months, the tumor may not yet have ac-
quired the 790 M mutation. However, this concept was
not supported by subsequent studies [28]. We specu-
lated that when the disease progresses after the first TKI
therapy, tumors have a dominant part of TKI-resistant
clones and a minor part of TKI-sensitive clones.
After the TKI holidays and owing to intercalation with
cytotoxic chemotherapies tumor redistribution occurred,
which lead to TKI-sensitive clones increasing, and TKI-
resistant clones decreasing. This redistribution was due
to higher sensitivity to cytotoxic chemotherapies in TKI-
resistant clones than that in TKI-sensitive clones. After
tumor redistribution by the intercalated chemotherapies,
tumor characteristics were more similar to those of
TKI-naïve tumors than to TKI-resistant tumors.
This can explain at least partly, why PFS of previous
TKIs has opposite influences in patients with or without
Fig. 3 Influence of baseline proinflammatory markers on overall
survival (OS) of patients who were readministered with tyrosine
kinase inhibitors (a) OS between patients with high and low baseline
neutrophil-to-lymphocyte ratio (NLR); (b) OS between patients with
high and low lymphocyte-to-monocyte ratio (LMR)
Fig. 4 Influence of trends of lymphocyte-to-monocyte ratio (LMR)
on overall survival (OS) of patients who were readministered with
tyrosine kinase inhibitors OS between patients with high and low
trend of LMR
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TKI holidays. However, this concept should be proved
with further studies.
Though several studies have reported on how clinical
factors affect the efficacies of TKI readministration
[10–12] patient heterogeneity is a confounding factor
that cannot be neglected. One study included more
than 70 % of patients without TKI holidays, whereas
two other studies included 32 and 50 % patients with
wild type EGFR mutation, respectively. We only in-
cluded EGFR-mutant NSCLC patients receiving first-
line EGFR-TKIs and at least one intercalated chemo-
therapy agent to decrease these confounding factors.
To the best of our knowledge, this is the first study
demonstrating that baseline NLR and trend of LMR are
prognostic factors in patients receiving EGFR-TKI read-
ministration. As a study aimed at patients receiving
third and later line therapies, the number of patients is
not small.
Our study had several limitations. First, data regarding
the amount and pattern of inflammatory cell infiltration
as well as the amount of tumor programmed death-ligand
1 expression in tumors were not available, which could
have provided us further information about the immune
condition in the tumor microenvironment [29]. Further
studies are required to determine whether immunother-
apy or anti-angiogenesis agents could prolong survival in
those who were speculated to have poor prognosis to TKI
readministration. Finally, our study was a retrospective
study a prospective trial is needed to validate these
results.
Conclusion
Longer PFS of first-line TKIs, low baseline NLR, and high
trend of LMR were good prognostic factors in EGFR-
mutant NSCLC patients receiving TKI readministration.
Table 1 Clinical factors and systemic inflammatory status of patients receiving EGFR-TKI readministration
Univariable analyses Multivariable analyses
Characteristics N (%) OS p Hazard ratio 95 % CI P value
Length of EGFR-TKI holiday 0.235
< 3 16 (20.0) 3.8
3–6 25 (31.3) 6.7
> 6 39 (48.8) 8.4
PFS of first-line EGFR-TKI 0.020 <0.001
< 6 17 (35.0) 3.5 4.970 2.170–11.382
6–12 35 (43.8) 7.2 1.818 0.899–3.678
> 12 28 (21.3) 9.9 1
Changes in the EGFR-TKI regimen 0.474
Yes 75 (93.8) 7.2
No 5 (6.2) 8.4
Type of EGFR-TKI readministrated 0.934
1st generation 71 (88.8) 7.0
2nd generation 9 (11.2) 7.4
Baseline NLR <0.001 0.037
> 5.2 27 (34.6) 3.2 2.352 1.052–5.256
≤ 5.2 51 (65.4) 8.4 1
Trend of NLR 0.129
> 110 % 44 (57.1) 4.3
≤ 110 % 33 (42.9) 8.4
Baseline LMR 0.006 0.632
> 2.5 37 (46.8) 8.3 1
≤ 2.5 41 (53.2) 4.2 1.197 0.574–2.497
Trend of LMR 0.037 0.004
> 50 % 45 (58.4) 7.9 1
≤ 50 % 32 (41.6) 4.1 2.651 1.374–5.118
Abbreviations: CI confidential interval, EGFR epidermal growth factor receptor, LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, OS overall
survival, PFS progression-free survival, TKI tyrosine kinase inhibitor
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Additional file 1: Lines and regimens of Intercalated chemotherapies.
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Abbreviations
EGFR: Epidermal growth factor receptor; LMR: Lymphocyte-to-monocyte
ratio; NLR: Neutrophil-to-lymphocyte ratio; NSCLC: Non-small cell lung
cancer; OS: Overall survival; PFS: Progression free survival; ROC: Receiver
operating characteristic; TKI: Tyrosine kinase inhibitor
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